178984-56-0

Basic information

• Product Name: 7-BENZYLOXY-4-CHLOROQUINOLINE
• Synonyms: 7-BENZYLOXY-4-CHLOROQUINOLINE;4-chloro-7-benzoxyquinoline;4-chloro-7-(phenylMethoxy;4-chloro-7-phenoxy-quinoline
• CAS NO: 178984-56-0
• Molecular Formula: C₁₆H₁₂ClNO
• Molecular Weight: 269.73
• Mol File: 178984-56-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 414.058 °C at 760 mmHg
• Flash Point: 204.215 °C
• Appearance: /
• Density: 1.264 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.654
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.86±0.27(Predicted)
• CAS DataBase Reference: 7-BENZYLOXY-4-CHLOROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BENZYLOXY-4-CHLOROQUINOLINE(178984-56-0)
• EPA Substance Registry System: 7-BENZYLOXY-4-CHLOROQUINOLINE(178984-56-0)

Safety Data

• Hazardous Substances Data: 178984-56-0(Hazardous Substances Data)

Usage

General Description

7-Benzyloxy-4-chloroquinoline is a chemical compound with the molecular formula C17H13ClNO. It is a quinoline derivative that contains a benzyl ether group and a chlorine substituent. 7-BENZYLOXY-4-CHLOROQUINOLINE has potential pharmaceutical applications, particularly as an intermediate in the synthesis of antimalarial and antiviral drugs. It may also have other biological activities, including as an antimicrobial and antifungal agent. Further research into the properties and potential uses of 7-benzyloxy-4-chloroquinoline is ongoing, and it is of interest to medicinal chemists and pharmaceutical scientists.

InChI:InChI=1/C16H12ClNO/c17-15-8-9-18-16-10-13(6-7-14(15)16)19-11-12-4-2-1-3-5-12/h1-10H,11H2

Upstream product

• 1484-26-0 3-(benzyloxy)aniline 
• 749922-34-7 7-(benzyloxy)quinolin-4(1H)-one 
• 909345-85-3 5-((3-(benzyloxy)phenylamino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 749922-34-7 7-(benzyloxy)quinolin-4-ol 
• 181950-57-2 4-chloro-7-hydroxyquinoline 
• 100-39-0 benzyl bromide 
• 68500-37-8 4-chloro-7-methoxyquinoline 
• 190516-85-9 7-methoxy-4(1H)-oxoquinoline 
• 536-90-3 m-Anisidine 
• 56881-19-7 Diethyl 2-<(3-methoxyphenylamino)methylene>malonate 
• 71083-05-1 7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid ethyl ester 

Downstream Products

• 1221443-46-4 N-(3-fluoro-4-(7-hydroxyquinolin-4-yloxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394820-98-4 4-(2-fluoro-4-nitrophenoxy)quinolin-7-ol 
• 1394820-99-5 1-((4-(2-fluoro-4-nitrophenoxy)quinolin-7-yl)oxy)-2-methylpropan-2-ol 
• 1394820-70-2 (R)-N-(3-fluoro-4-((7-(2-hydroxypropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-01-2 4-(4-amino-2-fluorophenoxy)quinolin-7-ol 
• 1394820-83-7 N-(4-((7-(2-hydroxy-2-methylpropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-03-4 4-(4-nitrophenoxy)quinolin-7-ol 
• 1394821-04-5 2-methyl-1-((4-(4-nitrophenoxy)quinolin-7-yl)oxy)propan-2-ol 
• 1394821-05-6 1-((4-(4-aminophenoxy)quinolin-7-yl)oxy)-2-methylpropan-2-ol 
• 1394820-85-9 N-(4-((7-(2-hydroxyethoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-06-7 2-((4-(4-nitrophenoxy)quinolin-7-yl)oxy)ethanol 
• 1394821-07-8 2-((4-(4-aminophenoxy)quinolin-7-yl)oxy)ethanol 
• 1394820-87-1 (R)-N-(4-((7-(2-hydroxypropoxy)quinolin-4-yl)oxy)phenyl)-1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide 
• 1394821-08-9 (R)-1-((4-(4-nitrophenoxy)quinolin-7-yl)oxy)propan-2-ol 

Relevant articles and documents

Design, synthesis, structure-activity relationships and mechanism of action of new quinoline derivatives as potential antitumor agents

A series of new quinoline derivatives was designed, synthesized and evaluated as potential antitumor agents. The results indicated that most compounds exhibited potent antiproliferative activity, and 7-(4-fluorobenzyloxy)–N-(2-(dimethylamino)- ethyl)quinolin-4-amine 10g was found to be the most potent antiproliferative agent against human tumor cell lines with an IC50 value of less than 1.0 μM. Preliminary structure-activity relationships analysis suggested that (1) the large and bulky alkoxy substituent in position-7 might be a beneficial pharmacophoric group for antiproliferative activity; (2) the amino side chain substituents in position-4 facilitated the antiproliferative activity of this class of compounds; and (3) the length of the alkylamino side chain moiety affected the antiproliferative potency, with two CH2 units being the most favorable. Further investigation of the mechanism of action of this class of compounds demonstrated that the representative compound 10g triggered p53/Bax-dependent colorectal cancer cell apoptosis by activating p53 transcriptional activity. Moreover, the results showed that compound 10g effectively inhibited tumor growth in a colorectal cancer xenograft model in nude mice. Thus, these quinoline derivatives might serve as candidates for the development of new antitumor drugs.

For antibacterial chlorine oxygen kui derivatives

The invention relates to an oxo-quinoline derivative with activity of resisting bacterial infection relevant diseases such as helicobacter pylori (Hp) infection disease. The invention specifically relates to a compound as shown in formula I in the specification, and a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R is selected from hydrogen, -C alkyl, -C alkenyl, -C alkynyl, or -C alkyl-phenyl, and the alkyl, alkenyl, alkynyl and phenyl can be randomly substituted by halogen, nitro, cyan, hydroxyl, -C alkoxy and phenyl; R is selected from hydrogen, -CONHR and -COOR, R and R are independently selected from -C alkyl and -C alkyl amino, and the amino is randomly substituted by one to two -C alkyls; R is selected from halogen, -C alkoxy, morpholinyl or piperazinyl.

BMP INHIBITORS AND METHODS OF USE THEREOF

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.